Device Trial Radar · NCT04124406
Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality
Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150,000
Planned (sponsor's estimate)
Start
Oct 18, 2019
Primary completion
Dec 31, 2023
Study completion Dec 2025
Sponsor
- Lead sponsor
- Exact Sciences CorporationNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Mayo Clinic
- First posted
- Oct 11, 2019
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
Conditions
- Colon Cancer
Interventions
CologuardDevice
multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
Primary outcomes
What the sponsor says the trial is designed to measure.
- Enrollment of SubjectsTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.